title: Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study.
abstract: Erlotinib is an oral, small-molecule targeting therapy that inhibits epidermal growth factor tyrosine kinase receptors. Erlotinib has been administered for the treatment of advanced pancreatic cancer and non-small cell lung cancer. In the present trial, erlotinib was administered as second-line monotherapy in pretreated patients with advanced non-small cell lung cancer. Our objectives were to determine response, survival and toxicity. Fifty-four patients pretreated with cisplatin or its analogue-based combinations were evaluated. The disease stage of the patients was IIIB and IV. Thirty-eight patients were male, 16 were female, the median age was 65 years, and the WHO performance status was 0-2. Twenty-five cases were adenocarcinomas, 19 squamous cell carcinomas and 10 were undifferentiated. Erlotinib was administered at a dose of 150 mg daily. In case of intolerable adverse reactions, the dose was either reduced to 100 mg daily or treatment was interrupted for a maximum of two weeks. A partial response was observed in 10 (18.52%) and stable disease in 40 (74.07%) patients. The median time to disease progression was 3 months (95% CI 1.7-10.3), and the median survival was 6 months. Concerning toxicity, 53 patients (98.15%) developed a grade 1-2 skin rash, and 1 (1.85%) grade 3. Diarrhea occurred in 9 (16.67%) patients, nausea and vomiting in 4 (7.41%) and gastritis in 2 (3.70%). The majority of patients tolerated the erlotinib treatment. Of note were the 18.52% response rate and 74.07% stable disease.
authors.affiliation: First Oncology Clinic, Errikos Dunant Hospital, Athens.
authors.forename: G P
authors.initials: GP
authors.lastname: Stathopoulos
authors.forename: D
authors.initials: D
authors.lastname: Trafalis
authors.forename: J
authors.initials: J
authors.lastname: Dimitroulis
authors.forename: A
authors.initials: A
authors.lastname: Athanasiou
authors.forename: J
authors.initials: J
authors.lastname: Koutantos
authors.forename: A
authors.initials: A
authors.lastname: Anagnostopoulos